Aflibercept in Polypoidal Choroidal Vasculopathy

Summary

To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration

Timeline

Start

2014-05-29

Primary completion

2016-08-12

Completion

2017-07-07

Publications

• Teo KYC, Yoon YH, Honda S, Park KH, Takahashi H, Ideta R, Sekiryu T, Hirata A, Obana A, Mori R, Chen SJ, Chee C, Wong JG, Lai TYY, Wong I, Fung N, Lee WK, Terasaki H, Chen SC, Miyatani T, Iida T, Obata R, Machewitz T, Leal S, Cheung CMG. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study. Ophthalmol Ther. 2026 Jun;15(6):1907-1924. doi: 10.1007/s40123-026-01366-5. Epub 2026 Mar 28.
• Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Cheung GCM, Zhang Z, Leal S, Ishibashi T; PLANET Investigators. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jul 1;136(7):786-793. doi: 10.1001/jamaophthalmol.2018.1804.

Drugs

Indications